Add like
Add dislike
Add to saved papers

[Neurotrophic therapy in the treatment of a comorbid patient with cerebrovascular pathology and diabetes mellitus].

OBJECTIVE: To study the use of Cellex in a population of patients aged 45 to 75 years with ischemic stroke and TIA, with a history of type 2 diabetes mellitus (T2DM), with diabetic distal symmetric polyneuropathy.

MATERIAL AND METHODS: The study involved 80 patients (men - 52.5%, women - 47.5%) in the rehabilitation period of stroke, including TIA, developed in T2DM. The patients were divided into 2 groups (40 people in each): in the 1st group, patients received Cellex 1.0 ml subcutaneously 1 time per day in addition to routine practice; the 2nd group received only routine practice. Cellex was prescribed in the form of two 10-day treatment courses with a break of 1 month. The range of patients examination during the whole study period (4 visits, 65 days) included an assessment of neurological symptoms (NIHSS, NISLL, DN-4, TSS scales), neurophysiological examination (EMNG), analysis of daily activity (SF-36 questionnaire, the Rivermead Mobility Index, the Modified Rankin Scale), the emotional state assessment on the scale and the effects of therapy on the Clinical Global Impression Scale.

RESULTS AND CONCLUSION: The clinical efficacy of the drug was shown in the form of an improvement of clinical parameters and data on EMNG of the lower extremities on the 60th day of the study. Improvement was observed in 17.5% of patients in the 1st group, while in the 2nd group deterioration was observed in 15.0% of patients, as evidenced by the presence of statistically significant differences. The study drug was also shown to be well tolerated and safe.

CONCLUSION: The use of the Cellex is effective and safe in patients with T2DM in the recovery period of stroke.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app